Idiopathic Pulmonary Fibrosis: Drugs
Commons · Question 27814 · Tabled 7 Sep 2026 · Department of Health and Social Care · Official record
Answered 22 Sep 2026
Question
Asked by Martin Wrigley
To ask the Secretary of State for Health and Social Care, what assessment she has made of trends in the levels of usage of the drug nerandomilast to treat pulmonary fibrosis.
Answer
Answered by James Frith, 22 Sep 2026
No assessment has been made. The National Institute for Health and Care Excellence is currently evaluating nerandomilast for treating idiopathic pulmonary fibrosis and progressive pulmonary fibrosis and expects final guidance to be issued in January 2027.